Sector Chart Summit Therapeutics Inc.

Stocks

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 18/08/2026 +03			5-day change	1st Jan Change
12.82 ^USD	+0.31%		-13.79%	-26.70%

08-12	Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC	MT
08-12	Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12	MT

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Sector Bio Therapeutic Drugs

	Capi.	Sales Growth	Profitability	Finances	EV / Sales	P/E
SUMMIT THERAPEUTICS INC.	10.2B	-	-	-	-	-
WUXI APPTEC CO., LTD.	73.25B
ARGENX SE	61.95B
INSMED INCORPORATED	28.02B					-
WUXI BIOLOGICS (CAYMAN) INC.	24.15B
BIONTECH SE	23.01B					-